# Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

> **NCT00968240** · PHASE1 · COMPLETED · sponsor: **Northwell Health** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

## Key facts

- **NCT ID:** NCT00968240
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968240, "Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00968240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*